Literature DB >> 35371633

A Case Report of CHEK2 and MUTYH Germline Mutations Associated With Cholangiocarcinoma in a Young Patient.

Obaid Rehman1, Bradley Sackfield1, Viveksandeep Thoguluva Chandrasekar2, Jorge Oliver1, Ganesh Aswath1.   

Abstract

Cholangiocarcinoma (CCA) is a major cause of primary liver carcinoma and has been associated with the penetrance of several germline mutations. We present a 31-year-old female evaluated for left upper quadrant pain and abnormal liver function tests. Ultrasound revealed a nodule in the liver, and biopsy showed intrahepatic adenocarcinoma. Germline testing was positive for two mutations: c.1100delC and c.1227_1228dupGG on the CHEK2 gene and the MUTYH gene, respectively. The patient was started on chemotherapy and tolerated it well. We aimed to demonstrate an association between CHEK2 and MUTYH mutations with CCA and highlight the importance of genetic testing for at-risk patients.
Copyright © 2022, Rehman et al.

Entities:  

Keywords:  chek2 mutation; cholangiocarcinoma; extrahepatic; intrahepatic; mutyh mutation

Year:  2022        PMID: 35371633      PMCID: PMC8959066          DOI: 10.7759/cureus.22631

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  15 in total

1.  Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination.

Authors:  Julie K Heimbach; William Sanchez; Charles B Rosen; Gregory J Gores
Journal:  HPB (Oxford)       Date:  2011-03-29       Impact factor: 3.647

Review 2.  The significance of genetics for cholangiocarcinoma development.

Authors:  Luca Maroni; Irene Pierantonelli; Jesus M Banales; Antonio Benedetti; Marco Marzioni
Journal:  Ann Transl Med       Date:  2013-10

3.  Genetic factors in the pathogenesis of cholangiocarcinoma.

Authors:  Christopher A Wadsworth; Peter H Dixon; Jason H Wong; Michael H Chapman; Siobhan C McKay; Amar Sharif; Duncan R Spalding; Stephen P Pereira; Howard C Thomas; Simon D Taylor-Robinson; John Whittaker; Catherine Williamson; Shahid A Khan
Journal:  Dig Dis       Date:  2011-06-17       Impact factor: 2.404

4.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

5.  Adenine DNA glycosylase activity of 14 human MutY homolog (MUTYH) variant proteins found in patients with colorectal polyposis and cancer.

Authors:  Masanori Goto; Kazuya Shinmura; Yusaku Nakabeppu; Hong Tao; Hidetaka Yamada; Toshihiro Tsuneyoshi; Haruhiko Sugimura
Journal:  Hum Mutat       Date:  2010-11       Impact factor: 4.878

Review 6.  Cholangiocarcinoma: Current Knowledge and New Developments.

Authors:  Boris Blechacz
Journal:  Gut Liver       Date:  2017-01-15       Impact factor: 4.519

Review 7.  Current perspectives on CHEK2 mutations in breast cancer.

Authors:  Panagiotis Apostolou; Ioannis Papasotiriou
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-05-12

8.  An association study between CHEK2 gene mutations and susceptibility to breast cancer.

Authors:  Manizheh Jalilvand; Mana Oloomi; Reza Najafipour; Safar Ali Alizadeh; Najmaldin Saki; Fatemeh Samiee Rad; Mohammad Shekari
Journal:  Comp Clin Path       Date:  2017-04-08

9.  MUTYH DNA glycosylase: the rationale for removing undamaged bases from the DNA.

Authors:  Enni Markkanen; Julia Dorn; Ulrich Hübscher
Journal:  Front Genet       Date:  2013-02-28       Impact factor: 4.599

10.  Risk of extracolonic cancers for people with biallelic and monoallelic mutations in MUTYH.

Authors:  Aung Ko Win; Jeanette C Reece; James G Dowty; Daniel D Buchanan; Mark Clendenning; Christophe Rosty; Melissa C Southey; Joanne P Young; Sean P Cleary; Hyeja Kim; Michelle Cotterchio; Finlay A Macrae; Katherine M Tucker; John A Baron; Terrilea Burnett; Loïc Le Marchand; Graham Casey; Robert W Haile; Polly A Newcomb; Stephen N Thibodeau; John L Hopper; Steven Gallinger; Ingrid M Winship; Noralane M Lindor; Mark A Jenkins
Journal:  Int J Cancer       Date:  2016-06-02       Impact factor: 7.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.